Citations

Mayo Clinic

Clear

920 citation(s) found for "Yu, Cheng".

Texture analysis of images using a two-dimensional fast time-frequency transform
Cheng, Chun Hing , Pradhan, Pyari Mohan , Mitchell, J. Ross , Mitchell, Joseph Ross, Mitchell, Joseph Ross

Journal of Medical Imaging | May 21, 2015 | Volume: 2 | Issue: 2 | Pages: 024504

10.1117/1.jmi.2.2.024504 | PMID 26158108 Get It

Incorporating approximate rotational invariance into two‐dimensional S‐transform
Cheng, Chun Hing , Pradhan, Pyari Mohan , Mitchell, J. Ross

IET Image Processing | April 1, 2015 | Volume: 9 | Issue: 7 | Pages: 535-544

10.1049/iet-ipr.2014.0765 Get It

The discrete two‐dimensional (2D) S‐transform (ST‐2D) is a space‐frequency representation that provides the local spectrum at each pixel in an image. The inherent localisation properties of the ST‐2D make it a preferred candidate for space‐frequency analysis. However, the ST‐2D is sensitive to the image rotation. This limits its use in many image processing applications such as texture analysis. This study describes the rotational sensitivity of the ST‐2D, and explains how this limits its application. To overcome these problems, a novel rotationally invariant S‐transform (RIST) is formulated, and its rotational invariance is investigated. The RIST can provide approximate rotational invariance for magnitudes and complex values over a wide range of rotation angles, but with a trade‐off of higher computation time. The RIST may be useful for many medical, scientific and industrial applications.
Outcomes and Resource Utilization of Endoscopic Mass‐Closure Technique for Laryngeal Clefts
Balakrishnan, Karthik , Cheng, Esther , Alarcón, Alessandro de , Sidell, Douglas R. , Rutter, Michael J. , Sidell, Douglas R. , Hart, Catherine K. , Sidell, Douglas R , Balakrishnan, Karthik

Otolaryngology–Head and Neck Surgery | March 17, 2015 | Volume: 153 | Issue: 1 | Pages: 119-123

10.1177/0194599815576718 | PMID 25782984 Get It

ObjectiveTo compare resource utilization and clinical outcomes between endoscopic mass‐closure and open techniques for laryngeal cleft repair.Study DesignCase series with chart review.SettingTertiary academic children’s hospital.Subjects and MethodsPediatric patients undergoing repair for Benjamin‐Inglis type 1‐3 laryngeal clefts over a 15‐year period. All 20 patients undergoing endoscopic repair were included. Eight control patients undergoing open repair were selected using matching by age and cleft type. Demographic, clinical, and resource utilization data were collected.ResultsTwenty‐eight patients were included (20 endoscopic, 8 open). Mean age, rates of tracheostomy and vocal fold immobility, and distribution of cleft types were not different between the 2 groups (all P >. 2). Mean operative time (P =. 004) and duration of hospital stay (P <. 001) were significantly shorter in the endoscopic group. All repairs were intact in both groups at final postoperative endoscopy. Rates of persistent laryngeal penetration or aspiration on swallow study were not different between groups (P = 1.000), although results were available for only 11 patients.ConclusionEndoscopic laryngeal cleft repair using a mass‐closure technique provides a durable result while requiring significantly shorter operative times and hospital stays than open repair and avoiding the potential morbidity of laryngofissure. However, open repair may allow the simultaneous performance of other airway reconstructive procedures and may be a useful salvage technique when endoscopic repair fails. Postoperative swallowing results require further study.
Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-Based Rigidity Analysis
Entezari, Vahid , Calderon, Nathan, Hipp, John A. , Villa‐Camacho, Juan C., Cheung, Felix H., Aboulafia, Albert J. , Turcotte, Robert , Anderson, Megan E. , Gebhardt, Mark C., Terek, Richard M. , Yaszemski, Michael J. , Snyder, Brian D. , Yaszemski, Michael, Nazarian, Ara , Zurakowski, David , Lin, Patrick P. , Cheng, Edward Y. , Damron, Timothy A.

Clinical Cancer Research | February 27, 2015 | Volume: 21 | Issue: 11 | Pages: 2514-2519

10.1158/1078-0432.ccr-14-2668 | PMID 25724521 Get It

Abstract Purpose: Pathologic fractures could be prevented if reliable methods of fracture risk assessment were available. A multicenter prospective study was conducted to identify significant predictors of physicians' treatment plan for skeletal metastasis based on clinical fracture risk assessments and the proposed CT-based Rigidity Analysis (CTRA). Experimental Design: Orthopedic oncologists selected a treatment plan for 124 patients with 149 metastatic lesions based on the Mirels method. Then, CTRA was performed, and the results were provided to the physicians, who were asked to reassess their treatment plan. The pre- and post-CTRA treatment plans were compared to identify cases in which the treatment plan was changed based on the CTRA report. Patients were followed for a 4-month period to establish the incidence of pathologic fractures. Results: Pain, lesion type, and lesion size were significant predictors of the pre-CTRA plan. After providing the CTRA results, physicians changed their plan for 36 patients. CTRA results, pain, and primary source of metastasis were significant predictors of the post-CTRA plan. Follow-up of patients who did not undergo fixation resulted in 7 fractures; CTRA predicted these fractures with 100% sensitivity and 90% specificity, whereas the Mirels method was 71% sensitive and 50% specific. Conclusions: Lesion type and size and pain level influenced the physicians' plans for the management of metastatic lesions. Physicians' treatment plans and fracture risk predictions were significantly influenced by the availability of CTRA results. Due to its high sensitivity and specificity, CTRA could potentially be used as a screening method for pathologic fractures. Clin Cancer Res; 21(11); 2514–9. ©2015 AACR.
Integration of Architectural and Cytologic Driven Image Algorithms for Prostate Adenocarcinoma Identification
Hipp, Jason, Monaco, James , Kunju, Lakshmi P., Cheng, Jerome , Yagi, Yukako , Emmert‐Buck, Michael R., Tomaszewski, John E. , Tompkins, Ronald G. , Flotte, Thomas J. , Lucas, David R. , Gilbertson, John R. , Rodriguez‐Canales, Jaime , Hewitt, Stephen M. , Feldman, Michael D. , Toner, Mehmet , Madabhushi, Anant , Balis, Ulysses J.

Analytical Cellular Pathology | January 12, 2015 | Volume: 35 | Issue: 4 | Pages: 251-265

10.1155/2012/294358 Get It

Introduction: The advent of digital slides offers new opportunities within the practice of pathology such as the use of image analysis techniques to facilitate computer aided diagnosis (CAD) solutions. Use of CAD holds promise to enable new levels of decision support and allow for additional layers of quality assurance and consistency in rendered diagnoses. However, the development and testing of prostate cancer CAD solutions requires a ground truth map of the cancer to enable the generation of receiver operator characteristic (ROC) curves. This requires a pathologist to annotate, or paint, each of the malignant glands in prostate cancer with an image editor software - a time consuming and exhaustive process.Recently, two CAD algorithms have been described: probabilistic pairwise Markov models (PPMM) and spatially-invariant vector quantization (SIVQ). Briefly, SIVQ operates as a highly sensitive and specific pattern matching algorithm, making it optimal for the identification of any epithelial morphology, whereas PPMM operates as a highly sensitive detector of malignant perturbations in glandular lumenal architecture.Methods: By recapitulating algorithmically how a pathologist reviews prostate tissue sections, we created an algorithmic cascade of PPMM and SIVQ algorithms as previously described by Doyle el al. [1] where PPMM identifies the glands with abnormal lumenal architecture, and this area is then screened by SIVQ to identify the epithelium.Results: The performance of this algorithm cascade was assessed qualitatively (with the use of heatmaps) and quantitatively (with the use of ROC curves) and demonstrates greater performance in the identification of malignant prostatic epithelium.Conclusion: This ability to semi-autonomously paint nearly all the malignant epithelium of prostate cancer has immediate applications to future prostate cancer CAD development as a validated ground truth generator. In addition, such an approach has potential applications as a pre-screening/quality assurance tool.
Findings of a Naloxone Database and its Utilization to Improve Safety and Education in a Tertiary Care Medical Center
Rosenfeld, David M. , Betcher, Jeffrey, Shah, Ruby A., Cheng, Meng‐Ru, Cubillo, Efrain I., Griffin, Julia, Trentman, Terrence L. , Betcher, Jeffrey A, Chang, Yu‐Hui H., Griffin, Julia M, Chang, Yu‐Hui

Pain Practice | January 7, 2015 | Volume: 16 | Issue: 3 | Pages: 327-333

10.1111/papr.12277 | PMID 25564757 Get It

AbstractIntroductionAnalyzing hospital naloxone use may assist in identification of areas for quality and safety improvement. Our primary objective is to quantitate the incidence of hospital naloxone use and to assess certain patient populations at risk.MethodsDuring the years 2008 to 2011, each clinical scenario where naloxone was administered on an in‐patient care ward was reviewed. The events were assessed to separate situations where naloxone rescue was effective in reversing opioid‐induced intoxication vs. others. Further analysis was conducted to stratify patient populations at greatest risk.ResultsNaloxone was administered for well‐defined opioid‐induced respiratory depression and oversedation 61% of the time, the remainder used for patient deterioration of other etiology. Surgical populations are at risk with an incidence of 3.8/1,000 hospitalized patients, and this is the greatest within 24 hours of surgery. General surgical patients represent the highest surgical patient risk at 5.5/1,000. Medical patients represent lower risk at 2.0/1,000. Patients with patient‐controlled analgesia and epidural opioid infusion are high risk at 12.1 and 13.1/1,000 patients, respectively. Many quality and safety interventions were gradually implemented in response to this data and are summarized. These include nursing and provider education, electronic medical record modification, and more stringent patient monitoring practices.ConclusionExamination of naloxone use can assist in the identification and stratification of patients at risk for opioid‐induced respiratory depression and oversedation and can serve as a driver for improvements in hospital patient safety. This information can also guide other institutions interested in similar improvements.
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults
Pérez-Andreu, Virginia, Zhang, Hui , Harvey, Richard C. , Payne-Turner, Debbie , Cheng, I-Ming, Carroll, William L. , Heerema, Nyla A. , Carroll, Andrew J. , Raetz, Elizabeth A. , Marcucci, Guido , Bloomfield, Clara D. , Mrózek, Krzysztof , Kohlschmidt, Jessica, Konopleva, Marina , Paietta, Elisabeth , Rowe, Jacob M. , Luger, Selina M. , Tallman, Martin S. , Dean, Michael , Torgerson, Dara G., Wang, Yanli , Relling, Mary V. , Evans, William E. , Gerhard, Daniela S., Loh, Mignon L. , Mullighan, Charles G. , Roberts, Kathryn G. , Xu, Heng Yi , Smith, Colton J. , Yang, Wenjian , Devidas, Meenakshi , Gastier‐Foster, Julie M. , Stock, Wendy , Kornblau, Steven M. , Burchard, Esteban G. , Yue, Feng , Pui, Ching-Hon , Jeha, Sima , Willman, Cheryl L. , Hunger, Stephen P. , Yang, Jun J.J. , Mullighan, Charles G , Harvey, Richard , Loh, Mignon L , Dean, Michael

Blood | December 3, 2014 | Volume: 125 | Issue: 4 | Pages: 680-686

10.1182/blood-2014-09-595744 | PMID 25468567 Get It

Key PointsIn this first ALL GWAS in AYAs, we determined that inherited GATA3 variants strongly influence ALL susceptibility in this age group. These findings revealed similarities and differences in the genetic basis of ALL susceptibility between young children and AYAs.
The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
Cheng, Su-Chun, Margolin, Kim , Clark, Joseph I. , Sosman, Jeffrey A. , Logan, Theodore F. , Curti, Brendan D. , Wong, Michael K. , Oleksowicz, Leslie, Vaishampayan, Ulka N. , Mier, James W., Panka, David J., Bhatt, Rupal S. , Bailey, Alexandra S. , Leibovich, Bradley C. , Kwon, Eugene D., Kabbinavar, Fairooz F. , Belldegrun, Arie S., Figlin, Robert A. , Pantuck, Allan J., Regan, Meredith M. , McDermott, David F. , Cheng, Su–Chun, Signoretti, Sabina , Dutcher, Janice P. , Ernstoff, Marc S. , Appleman, Leonard J. , Khushalani, Nikhil I. , Atkins, Michael B. , Vaishampayan, Ulka

Clinical Cancer Research | November 26, 2014 | Volume: 21 | Issue: 3 | Pages: 561-568

10.1158/1078-0432.ccr-14-1520 | PMID 25424850 Get It

Abstract Purpose: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2. Experimental Design: Standard HD IL2 was administered to prospectively evaluate whether the ORR of patients with mRCC with “good” predictive pathologic features based on an “integrated selection” model [ISM (e.g., clear-cell histology subclassification and carbonic anhydrase-9 (CA-9) IHC staining] was significantly higher than the ORR of a historical, unselected population. Archived tumor was collected for pathologic analysis including tumor programmed death-ligand 1 (PD-L1) expression. Results: One hundred and twenty eligible patients were enrolled between June 11 and September 7; 70% were Memorial Sloan Kettering Cancer Center (New York, NY) intermediate risk, 96% had clear cell RCC, and 99% had prior nephrectomy. The independently assessed ORR was 25% (30/120, 95% CI, 17.5%–33.7%, P = 0.0014; 3 complete responses, 27 partial responses) and was higher than a historical ORR. Thirteen patients (11%) remained progression free at 3 years and the median overall survival was 42.8 months. ORR was not statistically different by ISM classification (“good-risk” 23% vs. “poor-risk” 30%; P = 0.39). ORR was positively associated with tumor PD-L1 expression (P = 0.01) by IHC. Conclusions: In this prospective, biomarker validation study, HD IL2 produced durable remissions and prolonged survival in both “good” and “poor-risk” patients. The proposed ISM was unable to improve the selection criteria. Novel markers (e.g., tumor PD L1 expression) appeared useful, but require independent validation. Clin Cancer Res; 21(3); 561–8. ©2014 AACR.
Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk
Painter, Jodie N. , Batra, Jyotsna , Cheng, Timothy, Lose, Felicity , Dennis, Joe, Michailidou, Kyriaki , Ahmed, Shahana, Ferguson, Kaltin , Healey, Catherine S., Kaufmann, S., Hillman, Kristine M. , Walpole, Carina , Moya, Leire , Pollock, Pamela M. , Jones, Angela, Howarth, Kimberley, Martin, L. J., Gorman, Maggie, Hodgson, Shirley, (NSECG), National Study of Endometrial Cancer Genetics Group, Polanco, Ma. Magdalena Echeverry De, Sans, Monica, Carracedo, Angel, Castellvi-Bel, Sergi, Rojas-Martinez, Augusto, Santos, Erika, Teixeira, Manuel R., Carvajal-Carmona, Luis, Shu, Xiao-Ou, Long, Jirong, Zheng, Wei, Xiang, Yong-Bing, (ANECS), The Australian National Endometrial Cancer Study Group, Montgomery, Grant W., Webb, Penelope M., Scott, Rodney J., McEvoy, Mark, Attia, John, Holliday, Elizabeth, Martin, Nicholas G., Nyholt, Dale R., Henders, Anjali K., Fasching, Peter A., Hein, Alexander, Beckmann, Matthias W., Renner, Stefan P., Dörk, Thilo, Hillemanns, Peter, Dürst, Matthias, Runnebaum, Ingo, Lambrechts, Diether, Coenegrachts, Lieve, Schrauwen, Stefanie, Amant, Frederic, Winterhoff, Boris, Dowdy, Sean C., Goode, Ellen L., Teoman, Attila, Salvesen, Helga B., Trovik, Jone, Njolstad, Tormund S., Werner, Henrica M.J., Ashton, Katie, Proietto, Tony, Otton, Geoffrey, Tzortzatos, Gerasimos, Mints, Miriam, Tham, Emma, RENDOCAS, Hall, Per, Czene, Kamila, Liu, Jianjun, Li, Jingmei, Hopper, John L., Southey, Melissa C., (AOCS), Australian Ovarian Cancer Study, Ekici, Arif B., Ruebner, Matthias, Johnson, Nicola, Peto, Julian, Burwinkel, Barbara, Marme, Frederik, Brenner, Hermann, Dieffenbach, Aida K., Meindl, Alfons, Brauch, Hiltrud, Network, The GENICA, Lindblom, Annika, Depreeuw, Jeroen, Moisse, Matthieu, Chang-Claude, Jenny, Rudolph, Anja, Couch, Fergus J., Olson, Janet E., Giles, Graham G., Bruinsma, Fiona, Cunningham, Julie M., Fridley, Brooke L., Børresen-Dale, Anne-Lise, Kristensen, Vessela N., Cox, Angela, Swerdlow, Anthony J., Orr, Nicholas, Bolla, Manjeet K., Wang, Qin, Weber, Rachel Palmieri, Chen, Zhihua, Shah, Mitul, French, Juliet D., Pharoah, Paul D.P., Dunning, Alison M., Tomlinson, Ian, Easton, Douglas F., Edwards, Stacey L., Thompson, Deborah J., Spurdle, Amanda B., Webb, Penelope M. , Chenevix‐Trench, Georgia , Spurdle, Amanda B. , Brauch, Hiltrud , Dörk, Thilo , Cox, Angela , Giles, Graham G. , Southey, Melissa C. , Zheng, Wei , Shu, Xiao‐Ou , Long, Jirong , Dunning, Alison M. , Lindblom, Annika , Ekici, Arif B. , Czene, Kamila , Liu, Jianjun , Carracedo, Ángel , Hein, Alexander , Hillemanns, Peter , Lambrechts, Diether , Martin, Nicholas G. , Montgomery, Grant W. , Brenner, Hermann , Swerdlow, Anthony J. , Orr, Nick , Li, Jingmei , Bowtell, David D.L. , Weber, Rachel Palmieri , Nyholt, Dale R. , Rabstein, Sylvia , Lotz, Anne , Moisse, Matthieu , Teixeira, Manuel R. , French, Juliet D. , McEvoy, Mark , Njølstad, Tormund S. , Tham, Emma , Renner, Stefan P. , Henders, Anjali K. , Lambrechts, Diether , Rogatto, Sílvia Regina , Nicklin, James , Scott, Rodney J. , O’Mara, Tracy A. , Cheng, Timothy, Dennis, Joe, Tyrer, Jonathan P. , Ahmed, Shahana, Jones, Angela, Howarth, Kimberley, Gorman, Maggie, (NSECG), National Study of Endometrial Cancer Genetics Group, Polanco, Ma. Magdalena Echeverry De, Sans, Monica, Carracedo, Angel, Castellvi-Bel, Sergi, Rojas-Martinez, Augusto, Santos, Erika, Teixeira, Manuel R., Carvajal-Carmona, Luis, Shu, Xiao-Ou, Long, Jirong, Zheng, Wei, Xiang, Yong-Bing, (ANECS), The Australian National Endometrial Cancer Study Group, Montgomery, Grant W., Webb, Penelope M., Scott, Rodney J., McEvoy, Mark, Attia, John, Holliday, Elizabeth, Martin, Nicholas G., Nyholt, Dale R., Henders, Anjali K., Fasching, Peter A., Hein, Alexander, Beckmann, Matthias W., Renner, Stefan P., Dörk, Thilo, Hillemanns, Peter, Dürst, Matthias, Runnebaum, Ingo, Lambrechts, Diether, Coenegrachts, Lieve, Schrauwen, Stefanie, Amant, Frederic, Winterhoff, Boris, Dowdy, Sean C., Goode, Ellen L., Teoman, Attila, Salvesen, Helga B., Trovik, Jone, Njolstad, Tormund S., Werner, Henrica M.J., Ashton, Katie, Proietto, Tony, Otton, Geoffrey, Tzortzatos, Gerasimos, Mints, Miriam, Tham, Emma, RENDOCAS, Hall, Per, Czene, Kamila, Liu, Jianjun, Li, Jingmei, Hopper, John L., Southey, Melissa C., (AOCS), Australian Ovarian Cancer Study, Ekici, Arif B., Ruebner, Matthias, Johnson, Nicola, Peto, Julian, Burwinkel, Barbara, Marme, Frederik, Brenner, Hermann, Dieffenbach, Aida K., Meindl, Alfons, Brauch, Hiltrud, Network, The GENICA, Lindblom, Annika, Depreeuw, Jeroen, Moisse, Matthieu, Chang-Claude, Jenny, Rudolph, Anja, Couch, Fergus J., Olson, Janet E., Giles, Graham G., Bruinsma, Fiona, Cunningham, Julie M., Fridley, Brooke L., Børresen-Dale, Anne-Lise, Kristensen, Vessela N., Cox, Angela, Swerdlow, Anthony J., Orr, Nicholas, Bolla, Manjeet K., Wang, Qin, Weber, Rachel Palmieri, Chen, Zhihua, Shah, Mitul, French, Juliet D., Pharoah, Paul D.P., Dunning, Alison M., Tomlinson, Ian, Easton, Douglas F., Edwards, Stacey L., Thompson, Deborah J., Spurdle, Amanda B., Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Spurdle, Amanda B , Teixeira, Manuel R , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Swerdlow, Anthony J , Southey, Melissa C , Martin, Nicholas G , Rogatto, S R , Shu, Xiao-Ou , Dunning, Alison M , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Li, Jingmei , Ekici, Arif B , Moisse, Matthieu , Michailidou, Kyriaki , Chenevix-Trench, Georgia , Zheng, Wei , Czene, Kamila , Bowtell, David D , Batra, Jyotsna , Brauch, Hiltrud , Lindblom, Annika , Orr, Nick , Liu, Jing

Human Molecular Genetics | November 6, 2014 | Volume: 24 | Issue: 5 | Pages: 1478-1492

10.1093/hmg/ddu552 | PMID 25378557 Get It

Identification of a novel FN1–FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour
Lee, Jen‐Chieh , Jeng, Yung‐Ming , Su, Sheng-Yao, Wu, Chen‐Tu , Tsai, Keh‐Sung , Lee, Cheng‐Han , Lin, Chung‐Yen , Carter, Jodi M. , Huang, Jenq‐Wen , Chen, Shu-Hwa, Shih, Shyang‐Rong , Mariño‐Enríquez, Adrián , Chen, Chih-Chi, Folpe, Andrew L. , Chang, Yih‐Leong , Liang, Cher‐Wei , Chen, Shu‐Hwa , Marino-Enriquez, Adrian , Carter, Jodi

The Journal of Pathology | October 16, 2014 | Volume: 235 | Issue: 4 | Pages: 539-545

10.1002/path.4465 | PMID 25319834 Get It

Abstract Phosphaturic mesenchymal tumours ( PMTs ) are uncommon soft tissue and bone tumours that typically cause hypophosphataemia and tumour‐induced osteomalacia ( TIO ) through secretion of phosphatonins including fibroblast growth factor 23 ( FGF23 ). PMT has recently been accepted by the World Health Organization as a formal tumour entity. The genetic basis and oncogenic pathways underlying its tumourigenesis remain obscure. In this study, we identified a novel FN1–FGFR1 fusion gene in three out of four PMTs by next‐generation RNA sequencing. The fusion transcripts and proteins were subsequently confirmed with RT‐PCR and western blotting. Fluorescence in situ hybridization analysis showed six cases with FN1–FGFR1 fusion out of an additional 11 PMTs . Overall, nine out of 15 PMTs (60%) harboured this fusion. The FN1 gene possibly provides its constitutively active promoter and the encoded protein's oligomerization domains to overexpress and facilitate the activation of the FGFR1 kinase domain. Interestingly, unlike the prototypical leukaemia‐inducing FGFR1 fusion genes, which are ligand‐independent, the FN1–FGFR1 chimeric protein was predicted to preserve its ligand‐binding domains, suggesting an advantage of the presence of its ligands (such as FGF23 secreted at high levels by the tumour) in the activation of the chimeric receptor tyrosine kinase, thus effecting an autocrine or a paracrine mechanism of tumourigenesis. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.